Arrowhead Pharmaceuticals, Inc. (ARWR) is a Pasadena, California-based biotechnology company that develops RNA interference (RNAi) therapies, which silence the genes that drive disease. With a market value of roughly $8.2 billion and a share price that has pulled back sharply from its 52-week high, investors are weighing whether the stock can climb toward the $108 level that appears repeatedly in current analyst research.
The $108 central target is a calculated average, not a single firm's published number. Aggregating the most recent individually attributable targets, the Street's view spans a wide band. On the bullish end, Piper Sandler has reiterated a $126 target and H.C. Wainwright a $120 target. UBS initiated coverage at $109, and Citi has maintained a $108 target. Nearer the middle sit targets from firms such as J.P. Morgan ($88) and RBC Capital ($87). On the cautious side, Goldman Sachs resumed coverage with a Neutral rating and a $74 target, while a separate, older Bernstein target of $46 remains in some databases and illustrates how far apart analysts' base cases can be.
This dispersion reflects genuine disagreement about how much of Arrowhead's pipeline value should be discounted today. Bullish analysts emphasize the de-risking of the cardiometabolic franchise and optionality in obesity and central nervous system (CNS) programs. More cautious analysts argue the shares already price in substantial future execution on a product that is still early in its commercial ramp. The average analyst price target should be read as a statistical midpoint across those views, not a guaranteed stock forecast.
Arrowhead closed at $58.16 on November 6, 2026, near the middle of a 52-week range of $37.06 to $95.49. Reaching $108 would require a gain of roughly 85% from that level, a very large move by any measure. The stock is down about one-third over the past three months, a reminder that sentiment toward development-stage biotech can shift quickly even when clinical data is broadly positive.
The path toward $108 would likely require sustained, positive news flow across the pipeline. Arrowhead's approved drug, REDEMPLO (plozasiran), targets familial chylomicronemia syndrome, an ultra-rare condition causing severely elevated triglycerides, and the company is pursuing a broader label in severe hypertriglyceridemia. At the American Heart Association Scientific Sessions in early November 2026, pooled Phase 3 data showed plozasiran reduced acute pancreatitis event rates by 78% overall, strengthening the case for the broader indication. Arrowhead also reported interim ARO-MAPT data showing up to 73% reduction in cerebrospinal fluid tau, a marker relevant to Alzheimer's disease, extending the platform into the CNS.
Several factors could support appreciation toward $108. First, plozasiran's clinical profile is strong: sustained triglyceride reductions and hard-endpoint pancreatitis data give it a differentiated position, and the FDA has accepted the severe hypertriglyceridemia application into its STAR pilot program, potentially shortening the review timeline. Second, Arrowhead's RNAi platform continues to expand into new therapeutic areas, including obesity candidates ARO-INHBE and ARO-ALK7 and the ARO-DIMER-PA dual LDL/triglyceride candidate, providing multiple shots on goal. Third, partnerships with companies such as Novartis and Sarepta Therapeutics provide non-dilutive funding and validation, and Arrowhead reported roughly $1.6 billion in cash and securities as of mid-2026, supporting a multi-year runway.
The obstacles are substantial. Arrowhead remains unprofitable, with a trailing net loss of about $320 million, and the stock trades at no meaningful earnings multiple, making it sensitive to changes in risk appetite and interest rates. Competition is real: Ionis Pharmaceuticals' olezarsen is a direct rival in the same cardiometabolic market, and pricing and market-share dynamics in hypertriglyceridemia remain uncertain. Many of the programs that justify the highest price targets, including the obesity and CNS candidates, are still in early-stage trials, meaning a single disappointing readout could compress valuation quickly. A November 2026 refinancing of a $400 million credit facility improved terms but added debt to a company already carrying leverage.
From a technical standpoint, ARWR is trading below its 50-day moving average near $67 and its 200-day moving average near $72, which now act as overhead supply zones rather than support. The stock's 52-week high of $95.49 marks a significant resistance area, while $37.06 represents the major support floor from the past year. Reclaiming the $70s would be a meaningful first step, but a move to $108 would require clearing the prior high and establishing new territory, a structurally demanding setup given the current downtrend.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms apply different assumptions. Arrowhead reports fiscal year-end results on November 12, 2026, a key event for guidance and pipeline updates. Beyond that, investors should watch the severe hypertriglyceridemia regulatory path, additional obesity and CNS data readouts, prescription trends for REDEMPLO, partnership milestones, and any shifts in analyst ratings or price targets. Macroeconomic conditions, particularly Treasury yields and risk appetite toward unprofitable biotech, also matter.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like Arrowhead Pharmaceuticals, where sentiment can swing on clinical data and rate moves, such tools can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. Explore the AI Daily Buy/Sell Signals to see how the system currently reads the market.
The question of whether ARWR can reach $108 ultimately depends on execution across a pipeline whose most valuable programs are still maturing. The $108 central target, derived from roughly 15 analyst targets spanning $74 to $126, implies an approximate 85% advance from the current $58.16 price, a very large move that would require both continued clinical success and a favorable turn in sentiment toward biotech. Bullish arguments rest on plozasiran's strong cardiometabolic data, the REDEMPLO launch, and platform optionality in obesity and CNS disease. The counterweights are competition from Ionis, ongoing losses, and valuation sensitivity to interest rates. With fiscal year-end results due November 12 and multiple pipeline catalysts ahead, the path to $108 is conceivable but far from assured, and investors should weigh the wide analyst range before drawing any conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with AXON. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To ARWR | 1D Price Change % | ||
|---|---|---|---|---|
| ARWR | 100% | -0.49% | ||
| AXON - ARWR | 46% Loosely correlated | -0.21% | ||
| TSHA - ARWR | 43% Loosely correlated | -2.17% | ||
| IONS - ARWR | 42% Loosely correlated | -9.06% | ||
| DNLI - ARWR | 41% Loosely correlated | -2.36% | ||
| AMRN - ARWR | 40% Loosely correlated | +0.09% | ||
More | ||||